In the Claims:

- 1-43. (Canceled).
- 44. (Previously presented) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 114;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 114, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209367, wherein, the nucleic acid encoding said polypeptide is amplified in lung or colon tumors.
- 45. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 114.
- 46. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 114, lacking its associated signal peptide.

47-48. (Cancel).

- 49. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209367.
- 50. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 44 fused to a heterologous polypeptide.
- 51. (Previously presented) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.